Carregando...
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
Enzalutamide was the first novel androgen receptor signaling inhibitor to demonstrate an overall survival benefit in non-metastatic and metastatic castration-sensitive prostate cancer (CSPC). It has emerged as one of the most commonly prescribed oral prostate cancer therapies (ARSI) by medical oncol...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7778386/ https://ncbi.nlm.nih.gov/pubmed/33402834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S242921 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|